PPCB
Propanc Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · AU
$0.32
−7.31%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +70.3%
- EBIT
- +68.3%
- EPS
- +96.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +68.4%
- EBIT
- +68.3%
- Net income
- +68.0%
- EPS
- +95.3%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026